David D Chang Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for David D Chang.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of David D Chang. David D Chang is EVP, R&D, Chief Medical Off. in Kite Pharma, Inc. ($KITE) and President and CEO in Allogene Therapeutics, Inc. ($ALLO).
Latest Insider Trading Transactions of David D Chang
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 26 2021 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Option Exercise | M | 18.22 | 27,410 | 499,410 | 541,190 | |
| May 26 2021 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | M | 18.22 | 27,410 | 499,410 | 2,312,279 | 2.3 M to 2.3 M (+1.20 %) |
| Mar 17 2021 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Sell | S | 38.57 | 20,513 | 791,271 | 2,204,417 | 2.2 M to 2.2 M (-0.92 %) |
| Apr 28 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Gift | G | 0.00 | 428,022 | 0 | 650,266 | 222.2 K to 650.3 K (+192.59 %) |
| Apr 28 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Gift | G | 0.00 | 428,022 | 0 | 650,266 | 222.2 K to 650.3 K (+192.59 %) |
| Apr 28 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,187 | 0 | 2,224,101 | 2.2 M to 2.2 M (+0.41 %) |
| Apr 28 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,198 | 0 | 1,201,108 | 1.2 M to 1.2 M (+0.77 %) |
| Mar 20 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Option Exercise | A | 18.22 | 568,600 | 10,359,892 | 568,600 | |
| Mar 18 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Sell | S | 20.06 | 1,625 | 32,603 | 2,214,914 | 2.2 M to 2.2 M (-0.07 %) |
| Mar 18 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Sell | S | 19.24 | 18,710 | 360,012 | 2,215,426 | 2.2 M to 2.2 M (-0.84 %) |
| Mar 11 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,391 | 0 | 2,234,136 | 2.2 M to 2.2 M (+0.42 %) |
| Mar 11 2020 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,402 | 0 | 1,191,910 | 1.2 M to 1.2 M (+0.80 %) |
| Nov 21 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,391 | 0 | 2,224,745 | 2.2 M to 2.2 M (+0.42 %) |
| Nov 21 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,402 | 0 | 1,182,508 | 1.2 M to 1.2 M (+0.80 %) |
| Oct 29 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,391 | 0 | 2,215,354 | 2.2 M to 2.2 M (+0.43 %) |
| Oct 29 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,402 | 0 | 1,173,106 | 1.2 M to 1.2 M (+0.81 %) |
| Sep 25 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,391 | 0 | 2,205,963 | 2.2 M to 2.2 M (+0.43 %) |
| Sep 25 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,402 | 0 | 1,163,704 | 1.2 M to 1.2 M (+0.81 %) |
| Sep 09 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,391 | 0 | 2,195,469 | 2.2 M to 2.2 M (+0.43 %) |
| Sep 09 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,402 | 0 | 1,154,302 | 1.1 M to 1.2 M (+0.82 %) |
| Jul 22 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,391 | 0 | 2,186,078 | 2.2 M to 2.2 M (+0.43 %) |
| Jul 22 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 9,402 | 0 | 1,144,900 | 1.1 M to 1.1 M (+0.83 %) |
| Jul 12 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 6,388 | 0 | 2,176,687 | 2.2 M to 2.2 M (+0.29 %) |
| Jul 12 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 10,154 | 0 | 1,135,498 | 1.1 M to 1.1 M (+0.90 %) |
| May 15 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 11,753 | 0 | 1,125,344 | 1.1 M to 1.1 M (+1.06 %) |
| Apr 30 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | J | 0.00 | 11,753 | 0 | 1,113,591 | 1.1 M to 1.1 M (+1.07 %) |
| Mar 15 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Option Exercise | A | 26.89 | 292,700 | 7,870,703 | 292,700 | |
| Mar 15 2019 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Grant | A | 0.00 | 173,000 | 0 | 2,168,625 | 2 M to 2.2 M (+8.67 %) |
| Oct 17 2018 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Option Exercise | C | 0.00 | 5,704 | 0 | 0 | |
| Oct 17 2018 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | C | 0.00 | 29,946 | 0 | 1,101,838 | 1.1 M to 1.1 M (+2.79 %) |
| Oct 17 2018 | ALLO | Allogene Therapeut ... | Chang David D | President and CEO | Buy | P | 18.00 | 40,000 | 720,000 | 1,995,625 | 2 M to 2 M (+2.05 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | D | 46.09 | 90,600 | 4,175,754 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | D | 63.87 | 37,181 | 2,374,750 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | D | 63.87 | 28,919 | 1,847,057 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | D | 51.96 | 23,437 | 1,217,787 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | D | 51.96 | 51,563 | 2,679,213 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | D | 6.89 | 56,250 | 387,563 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | D | 6.89 | 116,750 | 804,408 | 0 | |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | D | 0.00 | 38,675 | 0 | 0 | 38.7 K to 0 (-100.00 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | U | 180.00 | 16,605 | 2,988,900 | 38,675 | 55.3 K to 38.7 K (-30.04 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Gift | G | 0.00 | 570 | 0 | 55,280 | 55.9 K to 55.3 K (-1.02 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Gift | G | 0.00 | 157 | 0 | 55,850 | 56 K to 55.9 K (-0.28 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Gift | G | 0.00 | 1,041 | 0 | 56,007 | 57 K to 56 K (-1.82 %) |
| Oct 05 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Gift | G | 0.00 | 375 | 0 | 57,048 | 57.4 K to 57 K (-0.65 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 179.66 | 7,927 | 1,424,196 | 57,423 | 65.4 K to 57.4 K (-12.13 %) |
| Sep 27 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Grant | A | 0.00 | 15,000 | 0 | 65,350 | 50.4 K to 65.4 K (+29.79 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 20,000 | 137,800 | 123,000 | |
| May 03 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 83.36 | 300 | 25,008 | 50,165 | 50.5 K to 50.2 K (-0.59 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 82.60 | 5,905 | 487,753 | 50,465 | 56.4 K to 50.5 K (-10.48 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 81.84 | 13,795 | 1,128,983 | 56,370 | 70.2 K to 56.4 K (-19.66 %) |
| May 03 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 20,000 | 137,800 | 70,165 | 50.2 K to 70.2 K (+39.87 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 20,000 | 137,800 | 143,000 | |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 83.66 | 700 | 58,562 | 50,165 | 50.9 K to 50.2 K (-1.38 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 82.60 | 8,697 | 718,372 | 50,865 | 59.6 K to 50.9 K (-14.60 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 82.00 | 3,549 | 291,018 | 59,562 | 63.1 K to 59.6 K (-5.62 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 80.44 | 2,424 | 194,987 | 63,111 | 65.5 K to 63.1 K (-3.70 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 79.63 | 3,939 | 313,663 | 65,535 | 69.5 K to 65.5 K (-5.67 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 78.53 | 691 | 54,264 | 69,474 | 70.2 K to 69.5 K (-0.98 %) |
| Apr 04 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 20,000 | 137,800 | 70,165 | 50.2 K to 70.2 K (+39.87 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 60,000 | 413,400 | 163,000 | |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 79.71 | 4,735 | 377,427 | 50,165 | 54.9 K to 50.2 K (-8.62 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 79.11 | 55,265 | 4,372,014 | 54,900 | 110.2 K to 54.9 K (-50.17 %) |
| Mar 02 2017 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 60,000 | 413,400 | 110,165 | 50.2 K to 110.2 K (+119.61 %) |
| Dec 27 2016 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | A | 46.09 | 90,600 | 4,175,754 | 90,600 | |
| Dec 27 2016 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Grant | A | 0.00 | 24,800 | 0 | 49,923 | 25.1 K to 49.9 K (+98.71 %) |
| Dec 22 2016 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 50.86 | 1,788 | 90,938 | 25,123 | 26.9 K to 25.1 K (-6.64 %) |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | A | 63.87 | 66,100 | 4,221,807 | 66,100 | |
| Dec 21 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Grant | A | 0.00 | 18,500 | 0 | 25,404 | 6.9 K to 25.4 K (+267.96 %) |
| Nov 12 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 30,800 | 212,212 | 223,000 | |
| Nov 12 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 80.02 | 30,800 | 2,464,616 | 6,904 | 37.7 K to 6.9 K (-81.69 %) |
| Nov 12 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 30,800 | 212,212 | 37,704 | 6.9 K to 37.7 K (+446.12 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 7,700 | 53,053 | 253,800 | |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 71.70 | 3,923 | 281,279 | 6,904 | 10.8 K to 6.9 K (-36.23 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 70.96 | 2,800 | 198,688 | 10,827 | 13.6 K to 10.8 K (-20.55 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 69.52 | 500 | 34,760 | 13,627 | 14.1 K to 13.6 K (-3.54 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 68.27 | 477 | 32,565 | 14,127 | 14.6 K to 14.1 K (-3.27 %) |
| Nov 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 7,700 | 53,053 | 14,604 | 6.9 K to 14.6 K (+111.53 %) |
| Oct 02 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 7,700 | 53,053 | 261,500 | |
| Oct 02 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 55.11 | 7,700 | 424,347 | 6,904 | 14.6 K to 6.9 K (-52.73 %) |
| Oct 02 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 7,700 | 53,053 | 14,604 | 6.9 K to 14.6 K (+111.53 %) |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 7,384 | 50,876 | 269,200 | |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 316 | 2,177 | 276,584 | |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 55.00 | 7,384 | 406,120 | 6,904 | 14.3 K to 6.9 K (-51.68 %) |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 7,384 | 50,876 | 14,288 | 6.9 K to 14.3 K (+106.95 %) |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 55.00 | 316 | 17,380 | 6,904 | 7.2 K to 6.9 K (-4.38 %) |
| Sep 08 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 316 | 2,177 | 7,220 | 6.9 K to 7.2 K (+4.58 %) |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 7,700 | 53,053 | 276,900 | |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 73.87 | 319 | 23,565 | 6,000 | 6.3 K to 6 K (-5.05 %) |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 72.93 | 2,205 | 160,811 | 6,319 | 8.5 K to 6.3 K (-25.87 %) |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 72.29 | 2,276 | 164,532 | 8,524 | 10.8 K to 8.5 K (-21.07 %) |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 71.15 | 2,900 | 206,335 | 10,800 | 13.7 K to 10.8 K (-21.17 %) |
| Aug 04 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 7,700 | 53,053 | 13,700 | 6 K to 13.7 K (+128.33 %) |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 7,700 | 53,053 | 284,600 | |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 62.97 | 1,410 | 88,788 | 6,000 | 7.4 K to 6 K (-19.03 %) |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 62.31 | 2,896 | 180,450 | 7,410 | 10.3 K to 7.4 K (-28.10 %) |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 61.15 | 3,394 | 207,543 | 10,306 | 13.7 K to 10.3 K (-24.77 %) |
| Jul 02 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 7,700 | 53,053 | 13,700 | 6 K to 13.7 K (+128.33 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | M | 6.89 | 7,700 | 53,053 | 292,300 | |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 58.04 | 2,541 | 147,480 | 6,000 | 8.5 K to 6 K (-29.75 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 56.93 | 2,726 | 155,191 | 8,541 | 11.3 K to 8.5 K (-24.19 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Sell | S | 55.93 | 2,433 | 136,078 | 11,267 | 13.7 K to 11.3 K (-17.76 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | M | 6.89 | 7,700 | 53,053 | 13,700 | 6 K to 13.7 K (+128.33 %) |
| Jun 17 2015 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Buy | P | 17.00 | 4,000 | 68,000 | 6,000 | 2 K to 6 K (+200.00 %) |
| Dec 30 2014 | KITE | Kite Pharma, Inc. | Chang David D | EVP, R&D, Chief Med ... | Option Exercise | A | 51.96 | 75,000 | 3,897,000 | 75,000 |
Page: 1